Dr. Sue Sisley has become a pivotal figure in the ongoing debate surrounding medical marijuana research in the United States. Known for her advocacy and research efforts, Dr. Sisley first garnered national attention after her dismissal from the University of Arizona while attempting to study the therapeutic potential of cannabis.
Challenges with the DEA
During an event in Las Vegas, Dr. Sisley announced that her research would continue at other universities, following her application for a third-party cannabis cultivation license from the DEA. The DEA had indicated it would accept such applications after years of criticism regarding the low-quality cannabis provided by federal sources for research. Currently, only one entity, Dr. Mahmoud ElSohly at the University of Mississippi, is allowed to cultivate cannabis for clinical studies, leading to concerns over the lack of competition and quality in federal cannabis research.
Research Implications
Dr. Sisley’s efforts are particularly significant as her research focuses on combat veterans suffering from PTSD and terminal cancer patients. However, nearly three years after the DEA’s promise to process third-party grower applications, no licenses have been issued. Although 33 reputable research institutions have submitted applications, the DEA has yet to process them despite collecting approximately $100,000 in fees. This stagnation raises serious questions about the future of cannabis research in the U.S.
Court Action and Legal Representation
In July, fed up with the delays, Dr. Sisley, alongside the Scottsdale Research Institute, pursued legal action against the DEA. Their attorneys, Matt Zorn and Shane Pennington, who took the case pro bono, argue that the DEA’s inaction constitutes a breach of due process. Despite an order from the court mandating a response from the DEA, the agency has not offered a satisfactory explanation for its delays, opting instead to open public comments on new rules for licensing.
Quality Control and Transparency Issues
Dr. Sisley is also vocal about the quality of cannabis produced by federal sources. She describes the DEA’s cannabis as poorly prepared and potentially contaminated, with testing revealing high levels of mold. This raises ethical concerns, especially when administering such products to vulnerable populations, including cancer patients.
Future of Cannabis Research
As the landscape of cannabis research evolves, Dr. Sisley advocates for FDA approval of cannabis as a legitimate medicine. The current federal model restricts research and limits access to high-quality cannabis, impeding advancements necessary for effective medical applications. Dr. Sisley underscores the importance of American-led research in advancing public health, as insurance companies will only fund approved treatments.
Conclusion
Amidst ongoing legislative discussions and the pressing need for expanded cannabis research, Dr. Sisley and her collaborators are aiming to challenge the status quo, illustrating the urgent need for regulatory reform in this critical area. The implications extend far beyond scientific inquiry, touching upon public health, patient care, and the burgeoning cannabis industry.
